Inovio Pharmaceuticals (INO) to Release Earnings on Tuesday

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data after the market closes on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.74) per share and revenue of $0.01 million for the quarter.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last posted its earnings results on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, beating analysts' consensus estimates of ($0.87) by $0.18. The business had revenue of $0.12 million during the quarter, compared to analysts' expectations of $0.03 million. On average, analysts expect Inovio Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Inovio Pharmaceuticals Stock Down 3.1 %

Inovio Pharmaceuticals stock opened at $1.86 on Tuesday. Inovio Pharmaceuticals has a 52-week low of $1.42 and a 52-week high of $13.44. The firm's fifty day moving average is $1.81 and its 200 day moving average is $2.70. The company has a market cap of $68.21 million, a price-to-earnings ratio of -0.47 and a beta of 1.40.

Wall Street Analyst Weigh In

A number of research analysts recently commented on INO shares. JMP Securities reaffirmed a "market outperform" rating and issued a $18.00 price target on shares of Inovio Pharmaceuticals in a report on Friday, January 10th. Royal Bank of Canada dropped their target price on Inovio Pharmaceuticals from $6.00 to $5.00 and set a "sector perform" rating for the company in a report on Wednesday, March 19th. StockNews.com lowered Inovio Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday. Finally, HC Wainwright reaffirmed a "neutral" rating and set a $3.00 price objective on shares of Inovio Pharmaceuticals in a research note on Wednesday, March 19th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $12.20.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.